We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Bayer Initiates a Phase III Study in Heart Failure Patients
Read MoreHide Full Article
Bayer Aktiengesellschaft (BAYRY - Free Report) announced the initiation of FINEARTS-HF, a placebo-controlled phase III study on finerenone. The study will investigate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction of ≥40%.
The primary objective of the study is to demonstrate the superiority of finerenone over placebo in reducing the rate of the composite endpoint of cardiovascular death and total (first and recurrent) heart failure (HF) events. Patients will be randomized to receive either finerenone once daily (titrated up to 40 mg) or placebo. The FINEARTS-HF study will assess whether the candidateleads to a reduction in the risk of cardiovascular death and other heart failure events in patients.
Finerenone (BAY 94-8862) is an investigational, non-steroidal, selective mineralocorticoid receptor antagonist that has been shown to block the harmful effects of the over-activated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. It is the first non-steroidal MR antagonist that is being developed in heart failure with preserved ejection fraction.
Shares of the company have lost 6.8% year to date compared with the industry’s decline of 5.3%.
The initiation of the FINEARTS-HF study is based onthe robust phase II studies ARTS-HF and ARTS-DN, which investigated the efficacy and safety of finerenone in patients with heart failure and chronic kidney disease (CKD), respectively.
Finerenone is already being investigated in large, long-term outcome studies in patients with CKDand type II diabetes (T2D).
We remind investors that, earlier this month, the company submitted regulatory applications seeking the approval of pipeline candidate, vericiguat, in the EU and Japan. Vericiguat is an experimental once-daily, first-in-class soluble guanylate cyclase (sGC)-stimulator being developed to treat patients with symptomatic chronic heart failure with an ejection fraction less than 45%, who have had a previous worsening heart failure event (defined as heart failure hospitalization or receiving an intravenous diuretic for heart failure without hospitalization), in combination with available heart failure therapies.
Bayer is developing the candidate in collaboration with Merck (MRK - Free Report) .
Novartis’ (NVS - Free Report) Entresto is approved to reduce the risk of death and hospitalization in people with certain types of long-lasting (chronic) heart failure.
Bayer is undertaking several initiatives to strengthen its position across portfolios, enhance efficiency and accelerate structural measures, including the decision to exit the Animal Health business unit. The company had earlier announced the divestment of its Animal Health business to Elanco (ELAN - Free Report) . Meanwhile, the Monsanto acquisition in 2018 has strengthened Bayer's position.
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year. These 7 were selected because of their superior potential for immediate breakout.
Image: Bigstock
Bayer Initiates a Phase III Study in Heart Failure Patients
Bayer Aktiengesellschaft (BAYRY - Free Report) announced the initiation of FINEARTS-HF, a placebo-controlled phase III study on finerenone. The study will investigate finerenone compared to placebo in more than 5,500 symptomatic heart failure patients with a left ventricular ejection fraction of ≥40%.
The primary objective of the study is to demonstrate the superiority of finerenone over placebo in reducing the rate of the composite endpoint of cardiovascular death and total (first and recurrent) heart failure (HF) events. Patients will be randomized to receive either finerenone once daily (titrated up to 40 mg) or placebo. The FINEARTS-HF study will assess whether the candidateleads to a reduction in the risk of cardiovascular death and other heart failure events in patients.
Finerenone (BAY 94-8862) is an investigational, non-steroidal, selective mineralocorticoid receptor antagonist that has been shown to block the harmful effects of the over-activated mineralocorticoid receptor (MR) system. MR overactivation is a major driver of heart and kidney damage. It is the first non-steroidal MR antagonist that is being developed in heart failure with preserved ejection fraction.
Shares of the company have lost 6.8% year to date compared with the industry’s decline of 5.3%.
The initiation of the FINEARTS-HF study is based onthe robust phase II studies ARTS-HF and ARTS-DN, which investigated the efficacy and safety of finerenone in patients with heart failure and chronic kidney disease (CKD), respectively.
Finerenone is already being investigated in large, long-term outcome studies in patients with CKDand type II diabetes (T2D).
We remind investors that, earlier this month, the company submitted regulatory applications seeking the approval of pipeline candidate, vericiguat, in the EU and Japan. Vericiguat is an experimental once-daily, first-in-class soluble guanylate cyclase (sGC)-stimulator being developed to treat patients with symptomatic chronic heart failure with an ejection fraction less than 45%, who have had a previous worsening heart failure event (defined as heart failure hospitalization or receiving an intravenous diuretic for heart failure without hospitalization), in combination with available heart failure therapies.
Bayer is developing the candidate in collaboration with Merck (MRK - Free Report) .
Novartis’ (NVS - Free Report) Entresto is approved to reduce the risk of death and hospitalization in people with certain types of long-lasting (chronic) heart failure.
Bayer is undertaking several initiatives to strengthen its position across portfolios, enhance efficiency and accelerate structural measures, including the decision to exit the Animal Health business unit. The company had earlier announced the divestment of its Animal Health business to Elanco (ELAN - Free Report) . Meanwhile, the Monsanto acquisition in 2018 has strengthened Bayer's position.
Bayer Aktiengesellschaft Price
Bayer Aktiengesellschaft price | Bayer Aktiengesellschaft Quote
Zacks Rank
Bayer currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Just Released: Zacks’ 7 Best Stocks for Today
Experts extracted 7 stocks from the list of 220 Zacks Rank #1 Strong Buys that has beaten the market more than 2X over with a stunning average gain of +24.1% per year. These 7 were selected because of their superior potential for immediate breakout.
See these time-sensitive tickers now >>